Putting poly (ADP-ribose) polymerase and other DNA repair inhibitors into clinical practice
- 1 November 2013
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Oncology
- Vol. 25 (6) , 609-614
Abstract
Poly (ADP-ribose) polymerase (PARP) and other DNA repair inhibitors are currently tested in numerous clinical trials, with variable success. Inhibitors are used in monotherapy, for example, PARP inhibitors in BRCA mutated cancers, or more widely in combination treatments. DNA repair inhibitors have, as chemotherapy, great potential for long-term disease control, or potentially even cures. However, the design of clinical trials using DNA repair inhibitors is intricate, as these inhibitors may also potentiate normal tissue toxicity without improving overall disease control. Recent findings of mechanism of action of PARP inhibitors and other DNA repair inhibitors are presented, and how the underlying genetic background and interplay between DNA repair pathways influence the choice of tumour location and combination strategies. The hallmark of individualized cancer therapy is to be able to genetically distinguish the responding subclass of cancer patients, and it is widely used when targeting oncogenes. The PARP inhibitors in BRCA mutated cancers also demonstrate that this approach is possible in a synthetic lethal context. There is strong proof-of-concept for DNA repair inhibitors being a useful anticancer strategy in well designed clinical trials.Keywords
This publication has 45 references indexed in Scilit:
- DNA repair dysregulation from cancer driver to therapeutic targetNature Reviews Cancer, 2012
- Homologous recombination in cancer development, treatment and development of drug resistanceCarcinogenesis, 2010
- Targeting the phosphoinositide 3-kinase pathway in cancerNature Reviews Drug Discovery, 2009
- Principles of Cancer Therapy: Oncogene and Non-oncogene AddictionCell, 2009
- An Oncogene-Induced DNA Damage Model for Cancer DevelopmentScience, 2008
- DNA repair pathways as targets for cancer therapyNature Reviews Cancer, 2008
- The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agentsJournal of Molecular Medicine, 2007
- Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpointsNature, 2006
- A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemiaBlood, 2004
- Disruption of the Fanconi anemia–BRCA pathway in cisplatin-sensitive ovarian tumorsNature Medicine, 2003